TuHURA Biosciences, Inc.

HURA Nasdaq SEC CIK 1498382
Follow TuHURA Biosciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$6.4M +9.8% vs same quarter last year
EPS, diluted −$0.10 +28.6% vs same quarter last year
Operating cash flow −$5M +54.8% vs same quarter last year
Revenue by quarter
$0
$0
$0
$0
$0
$0
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$40M−$20M$0$20MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$0−$31M
FY24$0−$23M
FY23$0−$15M
FY22-−$22.7M
FY21-−$38.3M
FY20-−$9.1M
FY19--
FY18-$11.1M
FY17--
FY16-$8.9M
FY15--
FY14--
FY13-−$8.3M
FY12$0−$2.4M
FY11$0−$1.3M
Free cash flowOperating cash flow minus capital expenditure
−$30M−$20M−$10M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$27.7M
FY24−$14.8M
FY23−$12M
FY22−$20.6M
FY21-
FY20-
FY19-
FY18-
FY17-
FY16-
FY15-
FY14-
FY13-
FY12-
FY11-